IBD | Individuals without IBD | |||||
---|---|---|---|---|---|---|
CDI identified by laboratory dataset | CDI identified by DAD | p value | CDI identified by laboratory dataset | CDI identified by DAD | p value | |
(n = 108) | (n = 110) | (n = 226) | (n = 201) | |||
Age Median (IQR) | 55.5(34–75) | 60 (40–75) | 0.49 | 74.5 (63–82) | 72 (61–82) | 0.38 |
% CD | 51 | 46 | 0.59 | |||
% Male | 44 | 47 | 0.59 | 43 | 42 | 0.77 |
Use 1 year prior | ||||||
5-ASA use (%) | 47.2 | 51.8 | 0.50 | |||
Thiopurine use (%) | 19.4 | 16.4 | 0.60 | |||
Anti-TNF use (%) | 7.4 | 10.9 | 0.48 | |||
Corticosteroid use (%) | 45.4 | 40.9 | 0.58 | |||
Use 3 month prior | ||||||
Any antibiotic use (%) | 50.0 | 50.9 | 1 | 50.0 | 49.2 | 0.92 |
Ciprofloxacin use (%) | 16.7 | 16.4 | 1 | 19.9 | 17.9 | 0.62 |
Metronidazole use (%) | 17.6 | 16.4 | 0.86 | 8.0 | 9.0 | 0.73 |
Clindamycin use (%) | Data too sparse to report N < 6 | Data too sparse to report N < 6 | 1 | 6.6 | 7.0 | 1 |
Hospitalization in the prior year (%) | 62 | 63.6 | 0.89 | 56.2 | 55.7 | 0.92 |
Surgery (%) | 23.2 | 20 | 0.62 | Data too sparse to report N < 6 | 3.0 | 0.76 |
Charlson comorbidity index score (%) | 0.41 | 0.90 | ||||
0 | 49.1 | 42.7 | 22.6 | 19.9 | ||
1 | 16.7 | 20 | 18.1 | 19.4 | ||
2 | 21.3 | 17.3 | 18.6 | 17.9 | ||
3+ | 13 | 20 | 40.7 | 42.8 | ||
Ambulatory care (%) | 0.98 | 0.87 | ||||
Lowest quartile | 11.1 | 10 | 15.5 | 15.9 | ||
2nd quartile | 15.7 | 14.6 | 25.2 | 23.9 | ||
3rd quartile | 34.3 | 34.6 | 21.7 | 24.9 | ||
Highest quartile | 38.9 | 40.9 | 37.6 | 35.3 |